Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02298959
Title Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

colorectal cancer

ovarian cancer

melanoma

renal cell carcinoma

Therapies

Aflibercept + Pembrolizumab

Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Moffitt Cancer Center-International Plaza Tampa Florida 33607 United States Details
Moffitt Cancer Center - McKinley Campus Tampa Florida 33612 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
National Cancer Institute Developmental Therapeutics Clinic Bethesda Maryland 20892 United States Details
National Institutes of Health Clinical Center Bethesda Maryland 20892 United States Details
Brigham and Women's Hospital Boston Massachusetts 02115 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
BCCA-Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
University Health Network-Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field